Dr. Xuehai Liang is Co-founder and CEO of Arnatar Therapeutics, Inc. He has more than 25 years of experience in RNA biology, antisense technology, and RNA-targeted drug discovery and development. Prior to founding Arnatar, Dr. Liang spent more than 12 years at Ionis Pharmaceuticals, where he served as Executive Director and led Core Antisense Research, advancing antisense mechanisms, oligonucleotide chemistry, and therapeutic discovery.

This session addresses disparities and structural barriers in liver disease care, along with predictive/ML-based tools and novel care delivery models (telehealth, quality measures) to improve outcomes.

This session showcases emerging prediction and diagnostic tools across hepatology, including AI-assisted guideline synthesis, novel fibrosis risk scores, and exercise-based interventions in cirrhosis.

This session focuses on chronic hepatitis D (delta), covering emerging therapies (bulevirtide, lonafarnib, novel entry inhibitors) and international epidemiologic data.

This session reviews progress toward functional cure in chronic hepatitis B, featuring phase 2/3 data on bepirovirsen, siRNA therapy, and immune correlates of HBsAg decline.

This session examines mechanisms of treatment resistance in hepatobiliary cancers, including tumor microenvironment and immune evasion pathways driving resistance to immunotherapy.

This session covers drug-induced liver injury across multiple contexts — statins, checkpoint inhibitors, acetaminophen, and GLP-1 agonists — using registry data, organoid models, and AI-based case triage tools.

This session examines factors modifying disease course in PSC and autoimmune hepatitis, including alcohol exposure, statin use, pruritus therapies, and post-transplant recurrence risk.

This session presents mechanistic studies of hepatic immune regulation, covering macrophage polarization, T cell responses in transplantation and cirrhosis, and circadian regulation of ischemia-reperfusion injury.

This session explores the interplay between frailty, metabolic health, and long-term outcomes across the liver transplant continuum. Presentations characterize frailty and cardiovascular-kidney-metabolic risk from candidacy through post-transplant recovery, and examine emerging therapeutic strategies—including GLP-1 receptor agonists—to improve survival and reduce cardiometabolic complications. Together, these studies highlight opportunities to refine risk stratification and intervene on modifiable factors that shape recipient outcomes.